Kimberly-Clark’s Kenvue Buyout: Accusations of Market Manipulation and Corruption
In a significant move, Kimberly-Clark is set to acquire Tylenol maker Kenvue in a $48.7 billion deal, creating a consumer goods powerhouse with a combined revenue of $32 billion. The agreement will see Kimberly-Clark shareholders owning approximately 54% of the combined entity, housing household brands like Listerine and Band-Aid alongside Huggies and Kleenex. This deal, one of the year’s largest, comes as Kenvue, a relatively young independent company spun off from Johnson & Johnson, has been under pressure from activist investors. The transaction, anticipated to close in the second half of next year pending shareholder approval, will result in cost savings and has led to shifts in both companies’ stock prices.
John Q. Hosedrinker